Changes in «pepsinogen-pepsin» system during development of tumor and nontumor gastric diseases

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Review includes data of studies the specialized proteolytic function of human stomach in cases of tumor and non-tumor pathologies. Screened results of research inside the «pepsinogen-pepsin» system provided on biochemical and molecular-biological levels can reflect the gradual changes of physiological state and function of gastric epithelium during development of pathologic processes.

It is showed that stomach specialized enzymes, for instance, pepsinogens, can be used as markers for early diagnostics of gastric cancer pathology as well as and as perspective differential-diagnostical indicators for nontumor gastric diseases.

Various research also displayed the data about protective role of "pepsinogen-pepsin" system in supporing of physiological functioning of human organism as well as possible participation in antiinfectional and antitumor processes.

About the authors

V. P. Kolinovsky

N. N. Petrov Research Institute of Oncology

Author for correspondence.
Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg

A. R. Shumakov

State Research Center Institute of Immunology

Email: shabanov@mail.rcom.ru
Russian Federation, Moscow

E. I. Tkachenko

St. Petersburg State Medical Academy

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg

References

  1. Вольфсон Н. И., Калиновский В. П., Петров А. С. Морфологические и молекулярно-биологические аспекты генеза экспериментального рака желудка // Вопр. онкол. 1985. № 6. С. 3-11.
  2. Калиновский В. П. Белки желудочного сока больных раком и другими заболеваниями желудка // Вопр. мед. химии. 1968. Т. 14. № 6. С. 572-577.
  3. Калиновский В. П., Гамаюнова В. Б., Шумакова А. Р., Хансон К. П. Радиоиммунологический анализ сывороточного пепсиногена І у больных хроническим гастритом и раком желудка // Вопр. онкол. 2000. T. 46. № 2. С. 153-155.
  4. Калиновский В. П., Приворотский В. Ф., Хансон К. П. Диагностическая и прогностическая значимость экспрессии тканеспецифических биомаркеров в опухолях и при других патологических состояниях желудка: Метод. реком. СПб., 2001. 106
  5. Минушкин О. Н., Зверков И. В. Хронический гастрит // Лечащий врач. 2003. № 3. С. 24-31. 6.
  6. Павлович И. М., Голофеевский В. Ю., Калиновский В. П. Хронический атрофический гастрит: особенности морфологической структуры и пепсинобразующей функции // Вопр. онкол. 2006. Т. 52. № 3. С. 353-356.
  7. Успенская М. Н., Калиновский В. П., Ткаченко Е. И., Хансон К. П. Инфекция Helicobacter pylori в свете современных представлений о гастроканцерогенезе и пепсин-пепсиноген-образующей функции желудка // Вопр. онкол. 2005. Т. 51. № 5. С. 533-539.
  8. Успенская М. Н., Калиновский В. П., Ткаченко Е. И. Биохимические и иммунологические критерии оценки состояния слизистой оболочки желудка при ее опухолевой и неопухолевой патологии // Вопр. онкол. 2007. Т. 53. № 3. С. 304-310.
  9. Шумаков А. Р., Калиновский В. П., Хансон К. П. Анализ полиморфизма генов пепсиногена А при раке желудка // Вопр. онкол. 1999. Т. 45. № 2. C. 129-130.
  10. Шумаков А. Р., Федоров С. Н., Калиновский В. П., Хансон К. П. Анализ экспрессии генов пепсиногена А при раке желудка // Вопр. онкол. 1999. Т. 45. № 3. С.238-240.
  11. Alfasser G., Antoniu B., Thayer S. P. et al. Degradation and inactivation of plasma tumor necrosis factor-alpha by pancreatic proteases in experimental acute pancreatitis // Pancreatology. 2005. Vol. 5. P. 37-43.
  12. Arveiler B., Breen H., Gosden J., Porteous D. Mарping human chromosome 11 with yeast artificial chromosome recombinants // Cytogenet. Cell Genet. 1991. Vol. 58. P. 1954-1955.
  13. Bodger K., Wyatt J. I., Heatley R. V. Variation in serum pepsinogens with severity and topography of Helicobacter pylori-associated chronic gastritis in dyspeptic patients referred for endoscopy // Helicobacter. 2001. Vol. 6. P. 216-224.
  14. Cao Q., Ran Z. H., Xiao S. D. Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin-17 and Helicobacter pylori immunoglobulin G antibodies // J. Dig. Dis. 2007. Vol. 8. P. 15-22.
  15. Chandrasoma P., Wickramasinghe K., Ma Y., De Meester T. Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia? // Dis. Esophagus. 2007. Vol. 20. P. 36-41.
  16. Chen T. S., Lee Y. C., Li F. Y., Chang F. Y. Smoking and hyperpepsinogenemia are associated with increased risk for duodenal ulcer in Helicobacter pyloriinfected patients // J. Clin. Gastroenterol. 2005. Vol. 39. P. 699-703.
  17. Crew K. D., Neugut A. I. Epidemiology of gastric cancer // World J. Gastroenterol. 2006. Vol. 12. P. 354-362.
  18. Derakhshan M. H., El-Omar E., Oien K. et al. Gastric histology, serological markers and age as predictors of gastric acid secretion in patients infected with Helicobacter pylori // J. Clin. Pathol. 2006. Vol. 59. P. 1293– 1299.
  19. Francesco de V., Zullo A., Rinaldi V. et al. Relationship between antral lymphocyte density and basal gastrin levels in patients with Helicobacter pylori infection // Dig. Liver Dis. 2000. Vol. 32. P. 676-681.
  20. Gisbert J. P., Boixeda D., Al-Mostafa A. et al. Basal and stimulated gastrin and pepsinogen levels after eradication of Helicobacter pylori: a 1-year follow-up study // Eur. J. Gastroenterol. Hepatol. 1999. Vol. 11. Р. 189-200.
  21. Gisbert J. P., Gonzalez L., Pedro de A. et al. Helicobacter pylori and bleeding duodenal ulcer: prevalence of the infection and role of non-steroidal anti-inflammatory drugs // Scand. J. Gastroenterol. 2001. Vol. 36. Р. 717–724.
  22. Hartleb M., Wandzel P., Waluga M. et al. Non-endoscopic diagnosis of multifocal atrophic gastritis; efficacy of serum gastrin-17, pepsinogens and Helicobacter pylori antibodies // Acta Gastroenterol. Belg. 2004. Vol. 67. P. 320-326.
  23. Hoek K. S., Milne J. M., Grieve P. A. et al. Antibacterial activity in bovine lactoferrin-derived peptides // Antimicrob. Agents Chemother. 1997. Vol. 41. Р. 54-59.
  24. Ichinose M., Miki K., Furihata C. et al. DNA methylation and expression of the rat pepsinogen gene in embryonic, adult and neoplastic tissues // Cancer Res. 1988. Vol. 48. P. 1603-1609.
  25. Ichinose M., Miki K., Wong R. N. S. et al. Methylation and expression of human pepsinogen genes in normal tissues and their alteration in stomach cancer // Jpn. J. Cancer Res. 1991. Vol. 82. Р. 686-692.
  26. Ikeda Y., Nishikura K., Watanabe H. et al. Histopathological differences in the development of small intestinal metaplasia between antrum and body of stomach // Pathol. Res. Pract. 2005. Vol. 201. P. 487–496.
  27. Ito M., Haruma K., Kaya S. et al. Serological comparison of serum pepsinogen and anti-parietal cell antibody levels between Japanese and German patients // Eur. J. Gastroenterol. Hepatol. 2002. Vol. 14. P. 123-127.
  28. Ito M., Haruma K., Kaya S. et al. Role of anti-parietal cell antibody in Helicobacter pylori-associated atrophic gastritis: evaluation in a country of high prevalence of atrophic gastritis // Scand. J. Gastroenterol. 2002. Vol. 37. Р. 287-293.
  29. Kalinovsky V. P., Likhatchev A. J., Shumakov A. R., Hanson K. P. Pepsinogen A gene, carcinogenesis and gastric cancer: biochemical and molecular-biological investigations // J. of BUON. 1998. Vol. 4. P. 341-346.
  30. Kalinovsky V. P., Volfson N. Y., Zaozerskaya L. A. et al. Molecular, biochemical and morphological aspects of the dynamics of rat stomach mucous membrane changes in experimental carcinogenesis induced by N-methyl-N-nitro-N-nitrosoguanidine (MNNG) // Arch. Geschwulstforsch. 1989. Vol. 59. P. 313-323.
  31. Karita M., Noriyasu A., Teramukai S., Matsumoto S. Atrophic progression induced by H. pylori infection is correlated with a changing pepsinogen I value and associated with the development of gastric cancer // Dig. Dis. Sci. 2004. Vol. 49. Р. 1615–1620.
  32. Kiyohira K., Yoshihara M., Ito M. et al. Serum pepsinogen concentration as a marker of Helicobacter pylori infection and the histologic grade of gastritis; evaluation of gastric mucosa by serum pepsinogen levels // J. Gastroenterol. 2003. Vol. 38. P. 332-338.
  33. Konturek P. C., Brzozowski T., Konturek S. J. et al. Mouse model of Helicobacter pylori infection: studies of gastric function and ulcer healing // Aliment. Pharmacol. Ther. 1999. Vol. 13. Р. 333-346.
  34. Konturek S. J., Zayachkivska O., Havryluk X. O. et al. Protective influence of melatonin against acute esophageal lesions involves prostaglandins, nitric oxide and sensory nerves // J. Physiol. Pharmacol. 2007. Vol. 58. P. 361-377.
  35. Kotani T., Murashima Y., Kobata A. et al. Pathogenic importance of pepsin in ischemia/reperfusioninduced gastric injury // Life Sci. 2007. Vol. 80. P. 984-1992.
  36. Kuhara T., Iigo M., Itoh T. et al. Orally administered lactoferrin exerts an antimetastatic effect and enchances production of IL-18 in the intestinal epithelium // Nutr. Cancer. 2000. Vol. 38. Р. 192–199.
  37. Kukacka J., Bibova J., Ruskoaho H.. Pelouch V. Protein remodeling of extracellular matrix in rat myocardium during four-day hypoxia: the effect of concurrent hypercapnia // Gen. Physiol. Biophys. 2007. Vol. 26. P. 133-142.
  38. Lee C. Т., KuoВ. I., Chen C. Y. et al. Helicobacter pylori clearance and serum gastrin and pepsinogen I concentrations in omeprazole treatment of duodenal ulcer patients // Eur. J. Clin. Pharmacol. 1999. Vol. 54. P. 817-820.
  39. Miki K., Urita Y. Using serum pepsinogens wisely in a clinical practice // J. Dig. Dis. 2007. Vol. 8. P. 8-14.
  40. Nagahama K., Yamato M., Nishio H., Takeuchi K. Essential role of pepsin in pathogenesis of acid reflux esophagitis in rats // Dig. Dis. Sci. 2006. Vol. 51. P. 303-309.
  41. Ohkusa T., Miwa H., Nomura T. et al. Improvement in serum pepsinogens and gastrin in long-term monitoring after eradication of Helicobacter pylori: comparison with H. pylori-negative patients // Aliment. Pharmacol. Ther. 2004. Vol. 20 (Suppl. 1). P. 25–32.
  42. Ohkusa T., Takashimizu I., Fujiki K. et al. Changes in serum pepsinogen, gastrin, and immunoglobulin G antibody titers in Helicobacter pylori-positive gastric ulcer after eradication of infection // J. Clin. Gastroenterol. 1997. Vol. 25. Р. 317-322.
  43. Oksanen A., Sipponen P., Karttunen R. et al. Atrophic gastritis and Helicobacter pylori infection in outpatents referred for gastroscopy // Gut. 2000. Vol. 46. P. 460-463.
  44. Oksanen A., Sipponen P., Miettinen A. et al. Evaluation of blood tests to predict normal gastric mucosa // Scand. J. Gastroenterol. 2000. Vol. 35. Р. 791-795.
  45. Roy M. K., Kuwabara Y., Hara K. Peptides from the N-terminal end of bovine lactoferrin induce apoptosis in human leukemic (HL-60) cells // J. Dairy Sci. 2002. Vol. 85. P. 2065-2074.
  46. Ruiz-Torres M. P., Perez-Rivero G., Rodriguez-Рuyol M. et al. The leukocyte-endothelial cell interactions are modulated by exracellular matrix proteins // Cell Physiol. Biochem. 2006. Vol. 17. P. 221-232.
  47. Ruol A., Parenti A., Zaninotto G. et al. Intestinal metaplasia is the probable common precursor of adenocarcinoma in barrett esophagus and adenocarcinoma of the gastric cardia // Cancer. 2000. Vol. 88. Р. 2520–2528.
  48. Sakai T., Banno Y., Kato Y. et al. Pepsin-digested bovine lactoferrin induces apoptic cell death with JNK/ SAPK activation in oral cancer cells // J. Pharmacol. Sci. 2005. Vol. 98. Р. 41-48.
  49. Samloff I. M., Stemmermann G. N., Heilbrun L. K., Nomura A. Elevated serum pepsinogen I and II levels differs as risk factors for duodenal ulcer and gastric ulcer // Gastroenterology. 1986. Vol. 90. P. 570-576.
  50. Santhosh S., Anandan R., Sini T. K., Mathew P. T. Protective effect of glucosamine against ibuprofen-induced peptic ulcer in rats // J. Gastroenterol. Hepatol. 2007. Vol. 22. P. 949-953.
  51. Schlemper R. J., van der Werf S. D., Biemond I., Laтers C. B. Seroepidemiology of gastritis in Japanese and Dutch male employees with and without ulcer disease // Eur. J. Gastroenterol. Hepatol. 1996. Vol. 8. P. 33-39.
  52. Shen B., Ormsby A. H., Shen C. et al. Cytokeratin expression patterns in noncardia, intestinal metaplasiaassociated gastric adenocarcinoma: implication for the evaluation of intestinal metaplasia and tumors at the esophagogastric junction // Cancer. 2002. Vol. 94. P. 820-831.
  53. Sipponen P., Ranta P., Helske T. et al. Serum levels of amidated gastrin-17 and pepsinogen I in atrophic gastritis: an observational case-control study // Scand. J. Gastroenterol. 2002. Vol. 37. P. 785-791.
  54. Sugiu K., Kamada T., Ito M. et al. Anti-parietal cell antibody and serum pepsinogen assessment in screening for gastric carcinoma // Dig. Liver Dis. Vol. 38. P.. 303-307.
  55. Suzuki H., Masaoka T., Hosoda H. et al. Plasma ghrelin concentration correlates with the level of serum pepsinogen I and pepsinogen I/II ratio - a possible novel and non-invasive marker for gastric atrophy // Hеpatogastroenterology. 2004. Vol. 51. Р. 1249–1254.
  56. Tatematsu M., Ichinose M., Tsukada S. et al. DNA methylation of the pepsinogen I gene during rat glandular stomach carcinogenesis // Jpn. J. Cancer Res. 1988. Vol. 79. P. 691-695.
  57. Vaananen H., Vauhkonen M., Helske T. et al. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study // Eur. J. Gastroenterol. Hepatol. 2003. Vol. 15. Р. 885–891.
  58. Voutilainen M., Mantynen T., Farkkila M. et al. Impact of non-steroidal anti-inflammatory drug and aspirin use on the prevalence of dyspepsia and uncomplicated peptic ulcer disease // Scand. J. Gastroenterol. 2001. Vol. 36. PР. 817–821.
  59. Yamada S., Matsuhisha T., Makonkawkeyoon L. et al. Helicobacter pylori infection in combination with the serum pepsinogen I/II ratio and interleukin-1 beta-511 polymorphisms are independent risk factors for gastric cancer in Thais // J. Gastroenterol. 2006. Vol. 41. Р. 1169-1177.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2008 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.